Table 1. Genes and pathways that support MLL-r leukemogenesis.
| Category | Molecule/domain | Relationship to MLL-FP | References |
|---|---|---|---|
| Constitutive protein interactors | MENIN/LEDGF | Direct interaction | [32,33,35,38] |
| CpG/PAF/CXXC | Direct interaction | [45,49–51,54,55] | |
| Sequence-specific interactors | c-MYB (& miR-150) | Direct interaction/Downstream | [59–61,64–66] |
| CREB/CBP/p300 | Direct interaction/Parallel | [68] | |
| AML1/RUNX1 family | Parallel/Downstream | [76,77,80–82] | |
| Transcriptional processivity-related | P-TEFb | Direct interaction | [84,85] |
| DOT1L | Direct interaction | [84,88,90–93] | |
| PRMT1 | Direct interaction | [95] | |
| Direction transcriptional target | HOXA7/HOXA9/CDXs | Downstream/Parallel | [97–99,115,116] |
| MEIS1/PBX2/PBX3 | Downstream | [102,103] | |
| EYA1/SIX1/DACH1 | Downstream | [107] | |
| miR-196b | Downstream | [108,111,112] | |
| MDS-EVI1, EVI1 | Downstream | [122,123] | |
| MEF2C | Downstream | [125–127] | |
| c-MYC | Downstream | [130,131] | |
| Signaling pathway | FLT3 | Parallel | [28,134,136,137] |
| RAS/MEK/ERK | Parallel | [61,139–141] | |
| Integrin β3/SYK | Parallel | [127] | |
| Wnt/β-catenin | Parallel | [145,146] | |
| NFκB | Parallel | [152] | |
| CEBPα/PU.1 | Parallel | [153,154] | |
| Histone modifying complex | EZH2/EED/SUZ12 | Parallel | [157,158] |
| BMI1 | Parallel | [162,163] | |
| CBX8 | Parallel | [164,165] | |
| KDM1A/LSD1 | Parallel | [167] | |
| MLL1 | Parallel | [169] | |
| Chromatin remodeling complex | RUVBL2 | Parallel | [171] |
| BRG1 | Parallel | [172] | |
| DNA methylation | DNMT1/3A/3B | Parallel | [175–177] |
| TET1 | Parallel | [179] |
The category of interaction with MLL-r alleles; name of the molecule, domain, or pathway; and reference numbers are shown. Genes are categorized as they are in the text into general pathways based on physical or functional data.